| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 21.6 | 26.1 |
| Profit before tax | 2.6 | 1.1 |
| Net income | 1.2 | 0.8 |
| EPS (diluted, $ a share) | $0.06 | $0.04 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +53.4% |
|---|---|
| Revenue, year on year | -17.1% |
| Operating margin | 12.4% |
10-Q filed with the SEC, NASDAQ: OPRX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
OptimizeRx Corp: key numbers
- Share price
- $6.64Close, Nov 16
- Market cap
- $126M
- Shares outstanding
- 18.91MLatest SEC cover page
- Sector
- Trade & Services
- Industry
- Services-Business Services, NECSIC 7389
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from OptimizeRx Corp
All →OptimizeRx Financial Results
OptimizeRx reported Q3 2026 revenue of $21.6 million, a 17% year-over-year decrease, while GAAP net income rose to $1.2 million. The company updated its full-year 2026 revenue guidance to $87-$93 million but maintained its adjusted EBITDA outlook. Management highlighted significant margin expansion and a reduction in debt principal to $10.4 million.
- Term
- Q3 2026
“Third quarter revenue and adjusted EBITDA both exceeded consensus expectations, reflecting continued margin expansion, disciplined execution, and the resilience of our operating model. While revenue declined year-over-year, adjusted EBITDA increased approximately 23%, with adjusted EBITDA margins expanding over 900 basis points, demonstrating the benefits of our improved product mix and cost management initiatives.”
Stephen L. Silvestro, OptimizeRx CEO
“While in-year contracted revenue continues to track below prior-year levels, resulting in a revision to our full-year 2026 revenue outlook, we remain encouraged by the growth we are seeing in contracted revenue for 2027, highlighting a start to a strong RFP season.”
Stephen L. Silvestro, OptimizeRx CEO